News
Cancer Research Publishes Matrix-Bio's Study on Detecting Breast Cancer Recurrence
WEST LAFAYETTE, Ind., October 20, 2010 – Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain, and ovarian cancer before succumbing to the disease in their early 50s.
“The original diagnosis was devastating, but the panic they felt during follow-up visits was even worse. It was agony to find a recurrence,” explains Krabbe, a retired insurance executive. “For me, it wasn’t if the cancer would come back in my sisters, it was when and would there be time to treat it.” Breast cancer recurrence occurs in more than 20 percent of breast cancer survivors.
So the news that a cancer recurrence detection blood test developed by Purdue Research Park-based company Matrix-Bio, Inc. has the potential to detect the recurrence of breast cancer a year in advance of currently available clinical diagnostic tests is something Krabbe applauds.Main Street Venture Funds Invests in Breast Cancer Recurrence Test
WEST LAFAYETTE, Ind., July 22, 2010 – Main Street Venture Fund has just given the estimated 200,000 women diagnosed with breast cancer each year new cause for hope. The Fort Wayne-based angel investment group is investing in Matrix-Bio, Inc., a Purdue Research Park company with new technology that shows great potential for early breast cancer detection and recurrence monitoring.
Purdue Research Park-Based Companies to Travel to Silicon Valley to Seek Funding
WEST LAFAYETTE, Ind. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Representatives of two Purdue Research Park-based companies launched from research developed at Purdue University will travel to California's Silicon Valley on May 18 to make formal presentations to venture capitalists.